Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

benzinga.com/news/health-care/25/09/47720147/roivant-priovants-experimental-drug-shows-promise-in-rare-skin-disease-trial

Roivant Sciences Ltd (NASDAQ:ROIV) and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).
Dermatomyositis is a chronic autoimmune disorder causing muscle inflammation and a distinctive skin rash, often purple or reddish,…

This story appeared on benzinga.com, 2025-09-17 16:13:24.
The Entire Business World on a Single Page. Free to Use →